Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948842 · ClinicalTrials.gov registry record · Phase 2
Clostridium Histolyticum Collagenase Injection for Urethral Disease
A Phase 2 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02948842: Completed Phase 2 study, sponsored by University of South Florida.
NCT02948842 is a Phase 2 study that has completed, run by University of South Florida. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02948842, a Phase 2 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of clostridium histolyticum collagenase (XIAFLEX®) in treating urethral strictures.
Primary Outcome
Number of subjects with complication after treatment with clostridium histolyticum collagenase
Interventions
- OTHER Saline
- DRUG Clostridium Histolyticum Collagenase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 2 |
What the finished NCT02948842 record still lists
NCT02948842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02948842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02948842 about?
NCT02948842 is a clinical study titled "Clostridium Histolyticum Collagenase Injection for Urethral Disease". The purpose of this study is to assess the efficacy of clostridium histolyticum collagenase (XIAFLEX®) in treating urethral strictures.
What is the current status of trial NCT02948842?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-05-22. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT02948842?
The interventions under investigation include: Saline (OTHER), Clostridium Histolyticum Collagenase (DRUG).
Who is sponsoring clinical trial NCT02948842?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02948842's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI